The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore ‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a common ...

In a first, the U.S. Food and Drug Administration has approved a treatment for cancer patients with specific genetic features in their tumors rather than a specific tumor type. The approval, based on ...

Combining the investigational immunotherapy agent IMM-101 with chemotherapy significantly improved the survival of patients with advanced pancreatic cancer, compared to those who received chemotherapy ...

Imfizi (durvalumab) has become the first approved immunotherapy in the United States for patients with advanced non-small cell lung cancer that has stabilized. The U.S. Food and Drug Admnistration ...

After failing to significantly extend survival in a confirmatory Phase 3 trial, Keytruda (pembrolizumab) will no longer be available in the U.S. for people with previously treated metastatic small ...

The U.S. Food and Drug Administration (FDA) has approved Imfinzi (durvalumab), in combination with standard chemotherapy, as an initial treatment of people with extensive-stage small cell lung cancer ...

Tumor cell vaccines are made from cancer cells removed from a patient during surgery. These cells are then killed and altered in the lab, with the aim of increasing the potential immune response ...

Viruses, like the flu virus, try to enter the cells in our body because they need a host to survive. Once inside, the virus begins to use the “machinery” of the cell to make copies of itself, ...

GBR 1342 is an antibody-based therapy being developed by Glenmark Pharmaceuticals to treat multiple myeloma and other cancers that overproduce CD38, a protein normally found on the surface of several ...

A planned safety review of a Phase 2 trial evaluating MDNA55 to treat glioblastoma has shown that the drug, developed by Medicenna Therapeutics is safe to deliver precisely into a patient’s tumor, ...

The European Commission has approved Opdivo (nivolumab) as a second-line treatment for adults with advanced inoperable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC), who ...

A combination of Keytruda (pembrolizumab) and Inlyta (axitinib) significantly extended the lives of patients with advanced renal cell carcinoma (RCC) and delayed disease progression or death, ...